Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05726825 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock

Study acronym: EXCHANGE-2
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Aug 31, 2026 to Feb 2028
    • Start date changed from estimate of Nov 28, 2023 to Feb 19, 2025
    • Study completion date: Jan 31, 2027 to Apr 2028
    • Site details revised at 25 of 25 sites
  2. Primary completion date: Aug 31, 2025 to Aug 31, 2026
    • Start date: Feb 28, 2023 to Nov 28, 2023
    • Study completion date: Jan 31, 2026 to Jan 31, 2027
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Randomized, prospective, multicenter, open-label, controlled, parallel-group interventional trial to test the adjunctive effect of therapeutic plasma exchange in patients with early septic shock.
Trial Details
NCT Number NCT05726825
Lead Sponsor Hannover Medical School
Conditions
(from sponsor)		 Septic Shock
Related terms Multiple Organ Failure, Sepsis, Shock, Septic
Enrollment 274 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov